ETON
$18.92
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases.
Recent News
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing
Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
February 2026's Top Growth Companies With Insider Influence
As February 2026 begins, U.S. stock markets have surged, with major indexes like the Dow Jones and S&P 500 showing strong gains amid positive economic developments such as a new trade deal with India. In this vibrant market environment, growth companies with high insider ownership can offer unique insights into potential success stories, as insiders' vested interests often align closely with shareholder value creation.
Insider Favorites: 3 Growth Stocks With Strong Ownership
In the midst of geopolitical tensions and market volatility, as seen with recent tariff threats impacting major indices, investors are increasingly seeking stability in assets with strong fundamentals. In such uncertain times, growth companies with high insider ownership can be particularly appealing, as they often signal confidence from those closest to the company's operations and future prospects.
Those who invested in Eton Pharmaceuticals (NASDAQ:ETON) three years ago are up 483%
It hasn't been the best quarter for Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders, since the share price has...
Highlighting December 2025's Growth Leaders With Insider Ownership
As the United States stock market grapples with concerns over an AI bubble, technology shares have been under pressure, causing declines in major indices like the Nasdaq and Dow Jones Industrial Average. In such a volatile environment, companies with strong growth potential and high insider ownership can offer investors a sense of stability and alignment of interests between management and shareholders.